Yahoo Finance

Tremfya vs. Cosentyx: Will IL-23s surpass IL-17s in the psoriasis market?

Data from the Phase III ECLIPSE head-to-head trial for Johnson & Johnson’s (J&J) interleukin 23 (IL-23) inhibitor Tremfya (guselkumab) in psoriasis patients showed that Tremfya was more effective than ...

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Johnson & Johnson's portfolio reshaping should enhance margins and long-term growth prospects. Click here to read why JNJ ...
PharmiWeb

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1The decision is supported by the ...
Healio

Tremfya nabs FDA approval for active ulcerative colitis, chasing competitor Skyrizi

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Johnson & Johnson’s Tremfya, a dual acting interleukin-23 inhibitor, for the treatment of ...
WebMD

Managing Ulcerative Colitis With Tremfya

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...
FiercePharma

Johnson & Johnson’s Tremfya tops Novartis blockbuster Cosentyx in head-to-head psoriasis showdown

Johnson & Johnson’s Tremfya may have made its debut after key rivals, but it made waves Wednesday in the next-gen psoriasis field with Cosentyx-topping head-to-head data. At the 48-week mark, 84.5% of ...
Monthly Prescribing Reference

Tremfya Approved for Children With Plaque Psoriasis, Psoriatic Arthritis

The recommended dosage for active PsA and moderate to severe plaque PsO in pediatric patients 6 years (≥40kg) is 100mg administered SC at week 0, 4, and then every 8 weeks thereafter. The Food and ...
Yahoo Finance

TREMFYA® (guselkumab) subcutaneous (SC) induction data support potential to be the first and only in its class to offer the option of both intravenous and SC induction therapy ...

"The Week 12 results from the ASTRO study build on data from the QUASAR study demonstrating that both guselkumab SC and IV induction achieved clinically differentiated results in patients with ...
Morningstar

New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...
PharmaTimes

Janssen’s Tremfya backed for NHS use

Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis. Janssen’s Tremfya has been recommended by NICE as a cost-effective treatment for plaque psoriasis.
Morningstar

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen

TREMFYA® offers the flexibility of self-administration from the start of treatment, building on the prior approval of subcutaneous induction in Crohn's disease TREMFYA® achieved significant rates of ...